Based on current operating plans, Xencor (XNCR) expects to end 2025 with between $535 million and $585 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2028.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- XNCR Upcoming Earnings Report: What to Expect?
- Xencor’s Promising Pipeline and Strategic Positioning Justify Buy Rating
- Xencor’s Promising Biotech Innovations and Strategic Growth Potential Justify Buy Rating
- Promising Outlook for Xencor’s XmAb942 Program Amidst Stock Decline